Skip to main content

Table 1 Characteristics of the Study population

From: Influenza vaccination and risk for cardiovascular events: a nationwide self-controlled case series study

  AMIa Strokea Pulmonary Embolisma
Total 5524 3434 994
Males, N (%) 3774 (68.3%) 1990 (57.9%) 510 (51.3%)
Higher-riskb, N (%) 5029 (91.0%) 3126 (91.1%) 859 (86.3%)
Lower-riskc, N (%) 495 (9.0%) 308 (8.9%) 136 (13.7%)
Mean age, years 67.2 (12.4) 69.9 (12.5) 63.4 (16.8)
  1. AMI acute myocardial infarction, SD standard deviation
  2. aOnly first-time AMI or Stroke or Pulmonary embolism cases occurring from May 1st, 2009 through 30th September 2010 or the day of emigration or death (whichever came first) were included
  3. bHigher risk was defined as being registered in the Norwegian Prescription Database for any of the following drugs: anti-diabetic drugs, anti-obesity drugs, anti-thrombotic drugs, glycosides, anti-arrhythmic drugs, nitrates, beta-blockers, calcium channel blockers, anti-hypertensive drugs, diuretics, peripheral vasodilators or other vasodilators, drugs acting on the renin-angiotensin system, vasoprotective drugs, lipid modifying agents and drugs for obstructive airway diseases from 1st January 2004 until vaccination
  4. cIn absence of prescriptions to these drugs, we defined individuals as being at lower risk